Femasys (FEMY)
(Delayed Data from NSDQ)
$0.93 USD
-0.04 (-3.78%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $0.92 -0.01 (-1.30%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FEMY 0.93 -0.04(-3.78%)
Will FEMY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FEMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FEMY
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
FEMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates
BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates
Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates
Other News for FEMY
Femasys secures first European order for FemBloc
Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global ...
Femasys secures first European order for FemBloc
Femasys announces achievement of regulatory approvals in Australia, NZ
Femasys Gains Momentum with EU Approval and Strategic Partnerships, Justifying Buy Rating